ANAB
AnaptysBio, Inc.
Biotechnology
Market Cap$2.90B
5Y Perf.+323.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ANAB vs DAWN
Revenue, margins, valuation, and 5-year total return — side by side.
DAWN
Day One Biopharmaceuticals, Inc.
Biotechnology
Market Cap$2.22B
5Y Perf.-9.5%
ANAB vs DAWN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ANAB | DAWN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $2.90B | $2.22B |
| Revenue (TTM) | $235M | $158M |
| Net Income (TTM) | $-13M | $-107M |
| Gross Margin | 99.0% | 89.1% |
| Operating Margin | 20.4% | -80.8% |
| Total Debt | $14M | $3M |
| Cash & Equiv. | $238M | $197M |
ANAB vs DAWN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ANAB
DAWN
| Stock | May 21 | May 26 | Return |
|---|---|---|---|
| AnaptysBio, Inc. (ANAB) | 100 | 423.4 | +323.4% |
| Day One Biopharmace… (DAWN) | 100 | 90.5 | -9.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANAB vs DAWN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ANAB leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Day One Biopharmaceuticals, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
ANAB
AnaptysBio, Inc.
The Growth Play
ANAB carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 157.0%, EPS growth 91.0%, 3Y rev CAGR 183.6%
- 494.5% 10Y total return vs DAWN's -8.4%
- 157.0% revenue growth vs DAWN's 20.6%
Best for: growth exposure and long-term compounding
DAWN
Day One Biopharmaceuticals, Inc.
The Income Pick
DAWN is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.35
- Lower volatility, beta 0.35, Low D/E 0.6%, current ratio 8.02x
- Beta 0.35, current ratio 8.02x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ANAB | 157.0% revenue growth vs DAWN's 20.6% |
| Quality / Margins | ANAB | -5.6% margin vs DAWN's -67.8% |
| Stability / Safety | DAWN | Beta 0.35 vs ANAB's 1.00, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ANAB | +402.3% vs DAWN's +208.0% |
| Efficiency (ROA) | ANAB | -3.6% ROA vs DAWN's -20.7%, ROIC 55.1% vs -30.5% |
ANAB vs DAWN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
ANAB vs DAWN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLANABLAGGINGDAWN
DAWNDay One Biopharmaceut…
1leads
ANABAnaptysBio, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs DAWNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ANAB6/6
Valuation MetricsMultiples, price ratios, and targets
ANAB2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ANAB5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
ANAB5/6
Risk & VolatilityBeta, volatility, and downside exposure
DAWN2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ANAB leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ANAB and DAWN operate at a comparable scale, with $235M and $158M in trailing revenue. ANAB is the more profitable business, keeping -5.6% of every revenue dollar as net income compared to DAWN's -67.8%. On growth, ANAB holds the edge at +151.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ANABAnaptysBio, Inc. | DAWNDay One Biopharma… |
|---|---|---|
| RevenueTrailing 12 months | $235M | $158M |
| EBITDAEarnings before interest/tax | $50M | -$124M |
| Net IncomeAfter-tax profit | -$13M | -$107M |
| Free Cash FlowCash after capex | $20M | -$108M |
| Gross MarginGross profit ÷ Revenue | +99.0% | +89.1% |
| Operating MarginEBIT ÷ Revenue | +20.4% | -80.8% |
| Net MarginNet income ÷ Revenue | -5.6% | -67.8% |
| FCF MarginFCF ÷ Revenue | +8.4% | -68.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +151.1% | +83.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.1% | +70.0% |
ANAB leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
ANAB leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ANABAnaptysBio, Inc. | DAWNDay One Biopharma… |
|---|---|---|
| Market CapShares × price | $2.9B | $2.2B |
| Enterprise ValueMkt cap + debt − cash | $2.7B | $2.0B |
| Trailing P/EPrice ÷ TTM EPS | -146.43x | -20.70x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 53.27x | — |
| Price / SalesMarket cap ÷ Revenue | 12.38x | 14.06x |
| Price / BookPrice ÷ Book value/share | 56.74x | 5.05x |
| Price / FCFMarket cap ÷ FCF | 148.12x | — |
ANAB leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ANAB leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
DAWN delivers a -23.4% return on equity — every $100 of shareholder capital generates $-23 in annual profit, vs $-24 for ANAB. DAWN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ANAB's 0.38x. On the Piotroski fundamental quality scale (0–9), ANAB scores 6/9 vs DAWN's 4/9, reflecting solid financial health.
| Metric | ANABAnaptysBio, Inc. | DAWNDay One Biopharma… |
|---|---|---|
| ROE (TTM)Return on equity | -24.5% | -23.4% |
| ROA (TTM)Return on assets | -3.6% | -20.7% |
| ROICReturn on invested capital | +55.1% | -30.5% |
| ROCEReturn on capital employed | +12.5% | -26.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.38x | 0.01x |
| Net DebtTotal debt minus cash | -$224M | -$194M |
| Cash & Equiv.Liquid assets | $238M | $197M |
| Total DebtShort + long-term debt | $14M | $3M |
| Interest CoverageEBIT ÷ Interest expense | 0.81x | — |
ANAB leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ANAB leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ANAB five years ago would be worth $39,484 today (with dividends reinvested), compared to $9,162 for DAWN. Over the past 12 months, ANAB leads with a +402.3% total return vs DAWN's +208.0%. The 3-year compound annual growth rate (CAGR) favors ANAB at 68.4% vs DAWN's 18.2% — a key indicator of consistent wealth creation.
| Metric | ANABAnaptysBio, Inc. | DAWNDay One Biopharma… |
|---|---|---|
| YTD ReturnYear-to-date | +124.8% | +143.3% |
| 1-Year ReturnPast 12 months | +402.3% | +208.0% |
| 3-Year ReturnCumulative with dividends | +377.4% | +65.1% |
| 5-Year ReturnCumulative with dividends | +294.8% | -8.4% |
| 10-Year ReturnCumulative with dividends | +494.5% | -8.4% |
| CAGR (3Y)Annualised 3-year return | +68.4% | +18.2% |
ANAB leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
DAWN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DAWN is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than ANAB's 1.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DAWN currently trades 100.0% from its 52-week high vs ANAB's 93.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ANABAnaptysBio, Inc. | DAWNDay One Biopharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.00x | 0.35x |
| 52-Week HighHighest price in past year | $72.36 | $21.53 |
| 52-Week LowLowest price in past year | $11.41 | $5.64 |
| % of 52W HighCurrent price vs 52-week peak | +93.1% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 75.6 | 80.3 |
| Avg Volume (50D)Average daily shares traded | 877K | 4.9M |
DAWN leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ANAB as "Buy" and DAWN as "Buy". Consensus price targets imply 10.3% upside for DAWN (target: $24) vs 9.7% for ANAB (target: $74).
| Metric | ANABAnaptysBio, Inc. | DAWNDay One Biopharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $73.88 | $23.75 |
| # AnalystsCovering analysts | 22 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.4% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ANAB leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). DAWN leads in 1 (Risk & Volatility).
Best OverallAnaptysBio, Inc. (ANAB)Leads 4 of 6 categories
Loading custom metrics...
ANAB vs DAWN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ANAB or DAWN a better buy right now?
For growth investors, AnaptysBio, Inc.
(ANAB) is the stronger pick with 157. 0% revenue growth year-over-year, versus 20. 6% for Day One Biopharmaceuticals, Inc. (DAWN). Analysts rate AnaptysBio, Inc. (ANAB) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ANAB or DAWN?
Over the past 5 years, AnaptysBio, Inc.
(ANAB) delivered a total return of +294. 8%, compared to -8. 4% for Day One Biopharmaceuticals, Inc. (DAWN). Over 10 years, the gap is even starker: ANAB returned +494. 5% versus DAWN's -8. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ANAB or DAWN?
By beta (market sensitivity over 5 years), Day One Biopharmaceuticals, Inc.
(DAWN) is the lower-risk stock at 0. 35β versus AnaptysBio, Inc. 's 1. 00β — meaning ANAB is approximately 181% more volatile than DAWN relative to the S&P 500. On balance sheet safety, Day One Biopharmaceuticals, Inc. (DAWN) carries a lower debt/equity ratio of 1% versus 38% for AnaptysBio, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ANAB or DAWN?
By revenue growth (latest reported year), AnaptysBio, Inc.
(ANAB) is pulling ahead at 157. 0% versus 20. 6% for Day One Biopharmaceuticals, Inc. (DAWN). On earnings-per-share growth, the picture is similar: AnaptysBio, Inc. grew EPS 91. 0% year-over-year, compared to -2. 0% for Day One Biopharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ANAB or DAWN?
AnaptysBio, Inc.
(ANAB) is the more profitable company, earning -5. 6% net margin versus -67. 8% for Day One Biopharmaceuticals, Inc. — meaning it keeps -5. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANAB leads at 20. 4% versus -80. 8% for DAWN. At the gross margin level — before operating expenses — ANAB leads at 99. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ANAB or DAWN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ANAB or DAWN better for a retirement portfolio?
For long-horizon retirement investors, Day One Biopharmaceuticals, Inc.
(DAWN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35)). Both have compounded well over 10 years (DAWN: -8. 4%, ANAB: +494. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ANAB and DAWN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(ANAB: 151.1% · DAWN: 83.9%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.